2. Academic Validation
  3. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

  • Mol Cancer. 2024 Apr 16;23(1):77. doi: 10.1186/s12943-024-01956-6.
Linyan Cheng 1,  Lujun Chen 2 3 4,  Yuan Shi 5,  Weiying Gu 1,  Weidong Ding 6 7,  Xiao Zheng 8 9 10,  Yan Liu 11,  Jingting Jiang 12 13 14,  Zhuojun Zheng 15
Affiliations

Affiliations

  • 1 Department of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
  • 2 Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
  • 3 Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, China.
  • 4 Institute for Cell Therapy of Soochow University, Changzhou, China.
  • 5 Laboratory of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, China.
  • 6 Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • 7 Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
  • 8 Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China. [email protected].
  • 9 Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, China. [email protected].
  • 10 Institute for Cell Therapy of Soochow University, Changzhou, China. [email protected].
  • 11 Department of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China. [email protected].
  • 12 Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China. [email protected].
  • 13 Jiangsu Engineering Research Center for Tumor Immunotherapy, Changzhou, China. [email protected].
  • 14 Institute for Cell Therapy of Soochow University, Changzhou, China. [email protected].
  • 15 Department of Hematology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China. [email protected].
PMID: 38627681 DOI: 10.1186/s12943-024-01956-6
Abstract

Emerging tumor immunotherapy methods encompass bispecific antibodies (BSABs), immune checkpoint inhibitors (ICIs), and adoptive cell immunotherapy. BSABs belong to the antibody family that can specifically recognize two different antigens or epitopes on the same antigen. These antibodies demonstrate superior clinical efficacy than monoclonal antibodies, indicating their role as a promising tumor immunotherapy option. Immune checkpoints are also important in tumor immunotherapy. Programmed cell death protein-1 (PD-1) is a widely acknowledged immune checkpoint target with effective anti-tumor activity. PD-1 inhibitors have demonstrated notable therapeutic efficacy in treating hematological and solid tumors; however, more than 50% of patients undergoing this treatment exhibit a poor response. However, ICI-based combination therapies (ICI combination therapies) have been demonstrated to synergistically increase anti-tumor effects and immune response rates. In this review, we compare the clinical efficacy and side effects of BSABs and ICI combination therapies in real-world tumor immunotherapy, aiming to provide evidence-based approaches for clinical research and personalized tumor diagnosis and treatment.

Keywords

Bispecific antibodies; Cancer; Efficacy; Immune checkpoint inhibitors; Safety.

Figures